Allspring SMID Core ETF
ASCE - ETF AI Analysis
Top Page
Allspring SMID Core ETF (ASCE)
ASCE, the Allspring SMID Core ETF, earns a solid overall rating largely because several of its key holdings—like Exelixis, Exlservice Holdings, SharkNinja, EverQuote, Pediatrix Medical Group, Teekay, Universal Health Services, and Vita Coco—combine strong financial performance with generally positive earnings call sentiment and supportive technical trends. The main drag comes from names such as Amneal Pharmaceuticals and SAIC, where overvaluation concerns and revenue challenges temper their otherwise decent momentum and fundamentals, and investors should note that the fund has meaningful exposure to company-specific risks like legal issues at Universal Health Services and geopolitical uncertainties at Teekay.
ASCE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 398.58M
- Region
- North America
- Expense Ratio
- 0.38%
- Beta
- 1.02
- Issuer
- Allspring
- Inception Date
- Jul 08, 2025
- Dividend Yield
- 0.18%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
ASCE Summary
Allspring SMID Core ETF (ASCE) is a U.S. stock fund that focuses on smaller and midsize companies rather than the big household-name giants, and it does not track a specific index. It spreads investments across many sectors, including technology, health care, and financials. Examples of companies it holds are Exelixis and Universal Health. Investors might consider ASCE for long-term growth and diversification, since smaller companies can have more room to expand. However, because it focuses on small and mid-sized stocks, the share price can be more volatile and may go up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.38%, which means you’ll pay about $3.80 per year for every $1,000 invested. That’s a bit higher than the average low-cost index ETF because this fund is actively managed, focusing on select small- and mid-cap value stocks rather than simply tracking a broad market index.
What would affect this ETF?
ASCE could benefit if the U.S. economy stays healthy, interest rates stabilize or fall, and smaller technology, health care, and consumer-focused companies continue to grow, helping its diverse mix of small and mid-sized stocks. On the downside, higher interest rates, an economic slowdown in the U.S., or sector-specific challenges in areas like health care, energy, and consumer cyclical names such as Abercrombie Fitch and SharkNinja could hurt performance, as smaller companies tend to be more sensitive to market stress.
ASCE Top 10 Holdings
ASCE leans into U.S. small and mid-cap names, with health care and energy quietly steering the ship. Biotech players like Exelixis and Amneal are rising, giving the fund a helpful lift, while Universal Health has been lagging and acting as a mild brake. On the energy side, Teekay and Chord Energy have been climbing steadily, adding some fuel to returns, even as National Fuel Gas looks more mixed. Consumer name SharkNinja is another bright spot, showing strong momentum and rounding out a domestically focused, sector-diverse lineup.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 EXEL | Exelixis | 3.44% | $13.70M | $17.22B | 64.51% | 78Outperform |
 AMRX | Amneal Pharmaceuticals | 3.27% | $13.05M | $7.45B | 81.67% | 58Neutral |
 EXLS | Exlservice Holdings | 3.00% | $11.97M | $6.68B | 10.99% | 79Outperform |
 UHS | Universal Health | 2.82% | $11.25M | $11.26B | -12.32% | 74Outperform |
 SN | SharkNinja, Inc. | 2.91% | $11.60M | $31.92B | 146.18% | 76Outperform |
 EVER | EverQuote | 2.46% | $9.82M | $994.28M | 11.39% | 77Outperform |
 MD | Pediatrix Medical Group | 2.54% | $10.14M | $2.47B | 39.10% | 76Outperform |
 SAIC | Science Applications | 2.51% | $10.02M | $6.39B | 66.53% | 71Outperform |
 COCO | Vita Coco Company | 2.45% | $9.78M | $3.76B | 56.02% | 74Outperform |
 BLBD | Blue Bird | 2.27% | $9.06M | $1.80B | 13.42% | 69Neutral |
ASCE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ASCE, the sentiment is Positive. The current price of 33.18 is above the 20-day moving average (MA) of 32.62, below the 50-day MA of 33.23, and above the 200-day MA of 32.03, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 75.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASCE.
ASCE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ASCE | $33.18 | $37.00(11.51% Upside) | $398.58M | 0.38% | 71Outperform |
 RSMC | $28.23 | $34.56(22.41% Upside) | $742.45M | 0.75% | 68Neutral |
 MSSM | $59.08 | $73.90(25.09% Upside) | $705.72M | 0.62% | 64Neutral |
 GRNJ | $25.85 | $38.59(49.27% Upside) | $408.20M | 0.75% | 69Neutral |
 SMIZ | $40.91 | $48.80(19.29% Upside) | $271.88M | 0.55% | 68Neutral |
 RNIN | $38.62 | $45.13(16.84% Upside) | $212.80M | 0.68% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ASCE | Allspring SMID Core ETF | 33.18 | 7.67 | 30.09% | |
| RSMC | Rockefeller U.S. Small-Mid Cap ETF | 28.23 | 2.92 | 11.55% | |
| MSSM | Morgan Stanley Pathway Small-Mid Cap Equity ETF | 59.08 | 10.35 | 21.23% | |
| GRNJ | Fundstrat Granny Shots US Small- & Mid-Cap ETF | 25.85 | 1.55 | 6.38% | |
| SMIZ | Zacks Small/Mid Cap ETF | 40.91 | 4.57 | 12.58% | |
| RNIN | Bushido Capital US SMID Cap Equity ETF | 38.62 | 11.91 | 44.57% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.